Skip to content
LUCEM

EXPLORE LUCEM

EMERGING HEALTH INSIGHTS
FOR A BRIGHTER TOMORROW

AOD-9604

A fragment of human growth hormone that went further through real drug development than almost any peptide sold online today — six human trials, a publicly traded company, a pivotal study of 536 people — and still didn't beat placebo.

What is it?A synthetic 16-amino-acid fragment of human growth hormone (hGH residues 176/177-191, with an added stabilizing tyrosine), engineered to isolate hGH's fat-metabolizing activity from its growth-promoting and blood-sugar-raising effects.15
Why are people interested?Fat loss, historically — it was developed and marketed specifically as an anti-obesity drug. More recently it's also discussed for joint/cartilage support.13
Human researchUnusually extensive and unusually conclusive: six completed human trials run by a real pharmaceutical company, culminating in a pivotal, adequately powered, placebo-controlled Phase 2b trial that did not meet its primary weight-loss endpoint.56
Animal & lab researchExtensive since the early 1990s — reduced fat gain in obese rodent models, plus a formal nonclinical toxicology program (genotoxicity, 6-month rat and 9-month primate chronic dosing) ahead of human trials.12345
Development & regulatory statusNot FDA-approved for any use. Classified in the FDA's most safety-restrictive compounding category since 2023, and — unlike several other peptides — was not among those removed from that category in 2026. Separately holds a narrower GRAS designation for use as a dietary-supplement ingredient. Prohibited at all times in Olympic and other WADA-governed sport.111215

What Are People Interested in AOD-9604 For?

Weight Loss & Fat Metabolism

Evidence: Strong Human Evidence

What the Research Says

This is the peptide's whole reason for existing, and it has the most complete — and most conclusively negative — human trial history of any compound on this site. Australian biotech Metabolic Pharmaceuticals ran six human clinical trials of AOD-9604 between roughly 1999 and 2006, including two Phase 2b efficacy trials.6 An earlier, higher-dose 12-week trial (METAOD005, ~300 subjects, doses up to 30 mg) reported a modest weight-loss signal — about 2.6 kg on active treatment versus roughly 0.8 kg on placebo.67 The pivotal follow-up trial (METAOD006, 536 subjects, 24 weeks, lower doses of 0.25-1 mg) was designed to confirm this at a dose selected for further development — and did not meet its primary weight-loss endpoint versus placebo.7 Development for the obesity indication was discontinued in 2007, and the compound was never advanced to Phase 3.78 The underlying animal rationale remains real and independently documented: AOD-9604 reduced fat gain in obese rats and mice without the insulin resistance or IGF-1 elevation seen with full-length growth hormone.1234

What the Real World Says

Despite the negative pivotal trial, AOD-9604 is still marketed online today as a fat-loss peptide, sometimes alongside GLP-1 drugs or other growth-hormone-related peptides — most of this marketing does not mention the Phase 2b result at all. Separately, AOD-9604 has real documented real-world use outside the clinic: it was one of the substances at the center of the 2013 Essendon Football Club (AFL) supplements scandal, in which a club sports scientist administered it to players; the case eventually led the World Anti-Doping Agency to confirm the substance was banned, and 32 players were later suspended over the broader program.1314

See the ResearchStudies, numbers and limits

The full human trial history

  • METAOD001-004: four early Phase I/IIa safety studies (IV and oral, single and multiple dose) in a combined ~91 healthy or clinically obese men, primarily assessing safety and tolerability rather than efficacy.6
  • METAOD005: Phase IIb, 12 weeks, ~300 obese adults, oral doses 1-30 mg — the trial that produced the encouraging early weight-loss signal.67
  • METAOD006: Phase IIb, 24 weeks, 536 obese adults, oral doses 0.25-1 mg — the pivotal trial, which did not meet its primary endpoint.7

An important transparency note

As far as we could confirm, the pivotal Phase 2b trial's primary results were never published as a full peer-reviewed paper — the negative finding is documented through a later academic review and the company's own public disclosures, not through the trial's own publication.7 This is a real gap: readers can't go read the primary data themselves in a journal, only secondary accounts of it.

Limitations

  • All human trials were sponsored by Metabolic Pharmaceuticals, the compound's developer — disclosed openly in the company's own safety publications, but still a single-sponsor evidence base.56
  • The Australian Therapeutic Goods Administration rejected an obesity indication for AOD-9604 following the Phase 2b result.7

Joint & Cartilage Support

Evidence: Mostly Animal & Lab Research

What the Research Says

This is a newer, much less developed angle than weight loss, and the evidence is preclinical only. Independent lab data describes AOD-9604 enhancing cartilage regeneration in a rabbit model of collagenase-induced knee osteoarthritis.9 No human trial of AOD-9604 for joint or cartilage outcomes has been conducted.

What the Real World Says

This is a growing marketing angle for AOD-9604 online, often pitched as a lower-risk alternative to other joint-focused peptides. We found no independent, structured real-world reporting substantial enough to assess how these claims hold up in practice — this appears to be marketing that has outpaced the (already thin) underlying research.

Other Areas People Talk About

Muscle Building

Research: We found no research — animal or human — supporting AOD-9604 for muscle building or anabolic effects. This is consistent with its original design rationale: it was specifically engineered to isolate hGH's fat-metabolizing activity while minimizing the growth-promoting effects associated with muscle and tissue growth.15

Real World: Despite this, some seller marketing describes AOD-9604 as effective for muscle building or as a general growth-hormone-like anabolic — a claim that runs directly against the compound's own documented mechanism and design intent, not just an evidence gap.

Real-World Use: What People Ask About

AOD-9604 is often discussed as a fat-loss or recovery peptide. Here is how to interpret the practical questions without confusing internet routines with tested human protocols.

What amounts do people discuss?›

🌎 Real World Says

Online peptide discussions describe amounts in micrograms and milligrams, but posts and seller guides are not reliable measures of typical use. The 1 mg/person/day figure sometimes quoted online comes from a particular food-ingredient GRAS determination; it is not a validated injectable dose or a demonstration of weight-loss efficacy.

🔬 Research Says

The developer conducted human trials, including two Phase 2b efficacy studies. The pivotal trial did not establish a meaningful weight-loss benefit. A tested research dose does not establish an effective self-use protocol.

Injection versus oral: does the route matter?›

🌎 Real World Says

People encounter injectable vials, oral products and claims that one route works better. The historical food-ingredient context is sometimes incorrectly used to imply injectable safety.

🔬 Research Says

Animal studies examined oral activity, and the human clinical program provides some tolerability information for its studied formulations. Those findings cannot be assumed to establish the safety, sterility, absorption or efficacy of today’s marketed injections.

Morning, fasting and cycle length›

🌎 Real World Says

Morning use, fasted use and multiweek “cycles” appear in peptide marketing and user conversations. These are descriptions of what is discussed, not independently verified community averages.

🔬 Research Says

There is no established timing strategy or cycle duration that makes AOD-9604 effective for fat loss. The negative efficacy findings cannot be fixed by assuming a different schedule works.

Stacking with GLP-1 drugs, BPC-157 or TB-500›

🌎 Real World Says

People sometimes discuss adding AOD-9604 to weight-management or recovery stacks, especially when hoping to target stubborn fat or joints. Personal reports cannot isolate which compound produced a change.

🔬 Research Says

The supplied research does not establish the safety or additional benefit of these combinations. The rabbit cartilage findings are not human joint-treatment evidence.

What changes and side effects do people report?›

🌎 Real World Says

Online experiences vary, including reports of no noticeable effect. A personal weight change cannot separate AOD-9604 from diet, exercise, other medications or normal fluctuation. Injection-site reactions and product-quality concerns are additional practical questions for injectable products.

🔬 Research Says

The published development program reported tolerability in studied settings, but long-term safety of current marketed products and combinations remains uncertain. Lack of proven weight-loss benefit is itself an important finding.

THE TAKEAWAY

AOD-9604 has more human trial history than many research peptides, but its major weight-loss trial did not show the hoped-for benefit. Current injection routines, stacks and cartilage claims have not been validated in human clinical trials.

What About Safety?

What We Know

  • AOD-9604 has an unusually thorough nonclinical safety package for a peptide in this space: genotoxicity testing (Ames test, chromosomal aberration assay), a 6-month chronic toxicology study in rats, and a 9-month chronic toxicology study in cynomolgus monkeys, none of which found evidence of meaningful toxicity at the doses tested.2
  • Across the human trial program, AOD-9604 did not raise IGF-1 levels and did not worsen oral glucose tolerance — the two effects that limit full-length growth hormone's safety profile — and no anti-AOD9604 antibodies were detected in any human study, indicating it isn't meaningfully immunogenic.6
  • AOD-9604 has an unusually short half-life (on the order of minutes in animal pharmacokinetic studies), rapidly broken down by sequential removal of amino acids from one end of the peptide.2

What We Don't Know

  • Long-term human safety data beyond the 24-week pivotal trial doesn't exist — no trial has followed people on AOD-9604 for longer than that.
  • Because the compound was never advanced past Phase 2b, there's no large-scale, real-world human safety database of the kind that exists for approved drugs.
  • Whether gray-market AOD-9604 products match the identity and purity of what was used in the original clinical trial program is not independently verified for any given product.

Reported / Identified Concerns

  • The core concern with AOD-9604 isn't safety — its own safety record is comparatively reassuring — it's that the human efficacy case for its original, most-marketed use (weight loss) did not hold up in the one trial designed to confirm it.7
  • Because the pivotal negative trial was never published in a peer-reviewed journal, most people encountering AOD-9604 marketing today have no easy way to find out that a well-powered trial of the compound already failed.7
  • Gray-market injectable products carry the standard identity/purity risks common to unregulated peptide sourcing, on top of the underlying efficacy question.

Is It Approved or Legal?

Status as of September 2026 — verify before relying on it, though this compound's regulatory position has been comparatively stable recently.

United States (FDA)

Investigational — restricted

Not approved for any therapeutic use. The FDA added AOD-9604 to "Category 2" (its significant-safety-risk compounding category) in September 2023, alongside roughly 18 other peptides.11 Unlike BPC-157, TB-500, MOTS-c and several others, AOD-9604 was not among the peptides the FDA removed from Category 2 in April 2026, and it was not one of the peptides reviewed by the FDA's Pharmacy Compounding Advisory Committee in July 2026 — its compounding restriction remains in place as of this build.12 Separately, AOD-9604 holds a narrower "Generally Recognized As Safe" (GRAS) determination, allowing its use as an ingredient in foods, drinks and dietary supplements at up to 1 mg per person per day — a food-safety designation, not a drug approval, and not applicable to injectable use.910

Australia (TGA)

Rejected for the obesity indication

AOD-9604's developer, Metabolic Pharmaceuticals, was an Australian company, and the Australian Therapeutic Goods Administration rejected an obesity indication for the compound following the Phase 2b trial's failure to meet its endpoint.7

Sport / WADA

Prohibited at all times

AOD-9604 is explicitly named as an example substance under WADA's Prohibited List, Section S2.3 (Growth Hormone fragments) — it has been banned in sport since 2012 and was central to a real doping case, not just a hypothetical risk category.131415

What We Still Don't Know

Why did the animal results not translate to people?

This isn't fully resolved. It's a recognized pattern across growth-hormone-and-fat-metabolism research generally — rodent fat-tissue biology doesn't always predict human results — but no dedicated mechanistic follow-up study explaining AOD-9604's specific human trial failure appears to exist.

Could a different dose, population, or combination have worked?

Unknown, and unlikely to be tested — Metabolic Pharmaceuticals discontinued the obesity program after the pivotal trial and the compound was never advanced to Phase 3.7

Does the joint/cartilage rationale hold up better than the weight-loss one did?

Genuinely unknown — this is preclinical-only, single-study evidence, in an animal model, for a compound whose only real human program tested it for a completely different indication and didn't succeed.9

Will the FDA ever reconsider AOD-9604's Category 2 status?

Not known. Unlike several other peptides reviewed in 2026, there's no indication a PCAC review of AOD-9604 is currently scheduled.

What would a real, validated human dose even look like, for any current marketed use?

For weight loss, the trialed doses (0.25 mg to 30 mg across different studies) didn't produce a confirmed effect at the dose ultimately chosen for the pivotal trial. For joint/cartilage use, no human dose has ever been tested at all.

Quality Matters Too.

Whether the research supports a compound, and whether a specific product actually contains what its label says, are two separate questions — and for AOD-9604, there's a third question worth asking first: whether the research actually supports the specific use it's being marketed for. The compound's real human trial history is a documented negative result for weight loss, its original and still-primary marketed use.

Beyond that evidence question, the standard gray-market concerns apply: no FDA-approved injectable product exists, so any injectable AOD-9604 comes from a compounding pharmacy or unregulated online seller with no built-in guarantee of identity, purity or accurate dosing. The one narrow legal pathway that does exist — GRAS status for dietary-supplement use at very low doses — doesn't extend to the higher-dose injectable products marketed for fat loss.

Explore Safety & Quality →

Research & References

Every claim on this page traces back to these sources. Open the studies and regulatory documents yourself.

HOW WE RATE THE EVIDENCE →
  1. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278 — peer-reviewed, foundational animal/mechanism study.Ng et al., Hormone Research 2000
  2. Moré MI, Kenley D. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. J Endocrinol Metab. 2014;4(3):64-77 — peer-reviewed, comprehensive nonclinical toxicology/pharmacokinetics summary; declared conflict of interest (co-author is Metabolic Pharmaceuticals' CEO and a Calzada Ltd shareholder).Moré & Kenley, Journal of Endocrinology and Metabolism 2014
  3. Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449 — peer-reviewed, animal.Heffernan et al., International Journal of Obesity 2001
  4. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189 — peer-reviewed, animal, mechanism study.Heffernan et al., Endocrinology 2001
  5. Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-507 — peer-reviewed, foundational animal study on oral bioactivity.Heffernan et al., American Journal of Physiology 2000 (cited via FDA public docket submission)
  6. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15 — peer-reviewed; summarizes all six human trials (METAOD001-006) run by the compound's developer; declared conflict of interest as in ref 2.Stier, Vos & Kenley, Journal of Endocrinology and Metabolism 2013
  7. AOD9604 — background summary including the Phase 2b trial design and outcome, citing Misra's 2013 review in Current Cardiology Reviews and the Sydney Morning Herald's contemporary reporting; cross-checked against the primary sources it cites.Wikipedia, cross-checked against cited primary/secondary sources
  8. Wallace N. Much ado about nothing: the peptide they say never worked. Sydney Morning Herald. 2013 Aug 2 — independent journalism on the Phase 2b trial's failure and its aftermath.Sydney Morning Herald, August 2013
  9. AOD-9604 (acetate) — product/technical reference citing cartilage-regeneration data in a rabbit collagenase-induced knee osteoarthritis model, and the compound's GRAS-related dosing context.Bioscience/Cayman Chemical product reference
  10. AOD9604 Receives GRAS Status — primary company (ASX-listed Calzada Limited) regulatory disclosure describing the conditional GRAS determination for dietary-supplement/food use at up to 1 mg/person/day.Calzada Limited, ASX announcement, June 2012
  11. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated September 29, 2023 — primary FDA source; AOD-9604 was added to Category 2 in this update.FDA, 503A Bulk Drug Substances Categories (September 2023, via A4PC)
  12. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated April 22, 2026 — primary FDA source; AOD-9604 does not appear among the peptides removed from Category 2 in this update.FDA, 503A Bulk Drug Substances Categories (April 2026)
  13. Supplement at centre of scandal banned WADA — AFL.com.au reporting confirming WADA's position that AOD-9604 was a banned substance, in the context of the Essendon Football Club supplements program.AFL.com.au, 2013
  14. AOD9604 never permitted — AFL.com.au reporting on the AFL/ASADA position regarding AOD-9604's banned status during the Essendon investigation.AFL.com.au
  15. World Rugby / WADA 2020 Prohibited List, Section S2.3 — official anti-doping document explicitly naming AOD-9604 as an example of a prohibited Growth Hormone fragment.World Rugby / WADA Prohibited List

Where to Next?

Safety & QualityHow to Read a Peptide COAExploreSee All Peptides A–ZLearnHow We Grade the Evidence

Still Confused?

Peptide research can get complicated quickly. If you'd rather talk it through with someone who can help you understand the terminology, research and questions worth asking:

General education only — not medical advice.

GET HELP UNDERSTANDING YOUR OPTIONS